Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raloxifene augmentation for schizophrenia spectrum disorders
2015-004483-11Phase 3Completed
- Sponsor
- University Medical Center Utrecht
- Start
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in schizophrenia, schizoaffective disorder, schizophreniform disorder and 1 more comparing Raloxifene augmentation with Placebo augmentation (2 arms). Primary endpoint: Primary: symptom severity. Started Feb 2016; status: completed.
02
Drugs
raloxifene
03
Conditions
schizophreniaschizoaffective disorderschizophreniform disorderSchizophrenia Spectrum Disorders (SSD)
Beyond the preview
Go deeper on 2015-004483-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004483-11.